DENTSPLY SIRONA Inc. Q4 FY2025 earnings call

2025 was important for Dentsply Sirona with steps to position for future. 2026 focused on executing return to growth action plan with five pillars: customer-centric mindset, reigniting sustainable growth, empowering performance, scaling the organization, financial strength. Actions include creating global customer service and technical service organization, increasing clinical education investment, launching new products, reorganizing commercial teams, hiring key sales leaders, establishing transformation office, strengthening board, initiating restructuring program, eliminating dividends and reallocating funds towards debt retirement and share repurchases.

Fourth quarter revenue was $961 million, with reported sales increase of 6.2% and constant currency growth of 2.5%. CTS segment: constant currency sales declined 1.9% due to lower sales in CAD-CAM in rest of world and Europe, partially offset by US growth. EDS segment: constant currency sales increased 4% with growth in rest of world across product categories. OIS segment: constant currency sales increased 6.9%, but IPS declined high single digits in quarter. Well-spec healthcare: constant currency sales increased 1.9%. Full-year 2025 sales were $3.68 billion, reported sales decline of 3% and constant currency decline of 4.3%. EDS growth in rest of world, imaging growth in Europe and rest of world, SureSmile growth in Europe, well-spec healthcare growth across regions.

2026 expected sales in range of $3.5 to $3.6 billion, negative 3% to negative 1% operational growth. Anticipate positive sequential sales momentum in second half. Adjusted earnings per share expected in range of $1.40 to $1.50, reflecting accelerated investments in innovation, clinical education, etc.

Questions and answers include topics like dividend elimination and capital deployment, impact of new dealer inventory model, timing and size of announcements with partners, R&D spend and product launches, commercial team reorganization, DSO strategy, market competition and pricing, free cash flow, implant business turnaround, Patterson agreement impact, etc.